Treatment of ARVI in young children

Objective. Summation of the results of monitoring the therapeutic efficacy of Orvirem in ARVI, including coronavirus infection (CVI) in children. Methods. When studying the therapeutic efficacy of Orvirem for patients with acute respiratory viral infections (stage 1), 453 children aged 1 to 6 years were under observation, and with CVI (CoV 229E and CoV OC43; stage 2) - 184 children of the same age group hospitalized on the 1-3rd day of disease onset. The etiology of acute respiratory viral infections was established by detecting pathogen antigens in the material from the nasal lumen and nasopharynx of patients by PCR or by immunofluorescence express test, followed by (after 2-3 days and before hospitaldischarge) determination of their retention or the appearance of new pathogens. Results. The inclusion of the drug in ARVI therapy at the early stages of the disease contributed to a more rapid elimination of the main symptoms of the disease (fever, intoxication, signs of catarrhal inflammation in the nasopharynx and larynx), and in the case of influenza and CVI caused by COV 229E and COV OC43 - elimination of the gastrointestinal syndrome. The cases of superinfection in those who received the drug were recorded 9.5 times less frequently than in the comparison group (p<0.001). Conclusion. A two-stage clinical and laboratory evaluation of the therapeutic efficacy and safety of the domestic drug Orvirem showed that its inclusion in the complex therapy of acute respiratory viral infections at the early stages of the disease contributes to the faster elimination of the main symptoms of the disease (fever, intoxication, signs of catarrhal inflammation in the nasopharynx and larynx), and in CVI - gastrointestinal syndrome, which ensures a faster return of children to daily activities.

acute respiratory viral infections, influenza, coronavirus infection, antiviral drugs, Orvirem, rimantadine, sodium alginate, children